Holen Sie sich die Stockscreener-App
6.95
10.14%
0.64
Schlusskurs vom Vortag:
$6.31
Offen:
$6.61
24-Stunden-Volumen:
2,582
Relative Volume:
0.28
Marktkapitalisierung:
$58.47M
Einnahmen:
$70,100
Nettoeinkommen (Verlust:
$-9.67M
KGV:
-6.0377
EPS:
-1.1511
Netto-Cashflow:
$-7.09M
1W Leistung:
+2.36%
1M Leistung:
+36.14%
6M Leistung:
-5.57%
1J Leistung:
-40.90%
1-Tages-Spanne:
$6.30
$6.92
1-Wochen-Bereich:
$6.30
$7.25
52-Wochen-Spanne:
$4.35
$18.40
Exozymes Inc Stock (EXOZ) Company Profile
Firmenname
Exozymes Inc
Sektor
Branche
Telefon
(626) - 415 - 1488
Adresse
750 ROYAL OAKS DR, MONROVIA
Compare EXOZ vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
6.30 | 58.57M | 70,100 | -9.67M | -7.09M | -1.1511 |
VRTX
Vertex Pharmaceuticals Inc
|
522.11 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.76 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.25 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.30 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.67 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exozymes Inc Aktie (EXOZ) Neueste Nachrichten
eXoZymes (EXOZ) Stock: Curia Deal Moves NCT Toward Commercial Production - Blockonomi
exozymes partners with Curia for NCT manufacturing scale-up - Investing.com
exozymes partners with Curia for NCT manufacturing scale-up By Investing.com - Investing.com India
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT - eagletribune.com
A 3,000-employee manufacturer will help eXoZymes move a product toward larger-scale production. - Stock Titan
Exozymes CEO Michael Heltzen buys $6,405 in company stock By Investing.com - Investing.com South Africa
Exozymes (EXOZ) CEO adds stock with August buys and grant - Stock Titan
eXoZymes Inc. (EXOZ) Edges Lower, Holding Support at $6.13 After 0.77% DipNAAIM Exposure - dars.gov.et
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - Barchart.com
eXoZymes Provides Fourth Quarter and Full Year 2024 Update - Barchart.com
eXoZymes Inc. (EXOZ) Holds Near $7.17 as Shares Trade Within Established RangePut Dominated - vinanet.vn
Primer: eXoZymes (EXOZ US)Aug 2026 - Smartkarma
Exozymes (EXOZ) CSO adds 32,964 shares from RSU vesting - Stock Titan
eXoZymes (EXOZ): Ends Up by 10.00% at $7.04; Trading Range: the Near-Term Reference Band Stretches From $6.69 to $7.39 in the Available RecordKey Reversal Day - vinanet.vn
eXoZymes Q2FY26 Results: Net loss widens to $2.88M, raises $6M - scanx.trade
eXoZymes Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: eXoZymes posts q2 2026 loss as launch plans advance - Investing.com
EXOZ: NCT program exceeded targets; $6M raised and $2M NIH grant secured for R&D and commercialization - TradingView
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today - The Batesville Daily Guard
exoZymes reports 10-fold productivity gain in NCT manufacturing By Investing.com - Investing.com Canada
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets - ACCESS Newswire
EXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets - marketscreener.com
exoZymes reports 10-fold productivity gain in NCT manufacturing - Investing.com
Will eXoZymes (NASDAQ:EXOZ) Spend Its Cash Wisely? - webull.com
eXoZymes Inc. (EXOZ) Drops 3% to $5.82, Pressuring Key Support at $5.53Narrow Range Breakout - vinanet.vn
MDB Capital Holdings (MDBH) records $16.1M H1 2026 loss and $33.1M eXoZymes stake - Stock Titan
EXOZYMES INC. 2Q 2026: Revenue $0 Net loss $(5.25M) — 10-Q Summary - TradingView
EXoZymes, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
eXoZymes Inc (EXOZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
eXoZymes Q2 Results: Update call scheduled for August 20 - scanx.trade
eXoZymes CEO to Lead Q2 Results Webinar With Q&A Aug. 20 - Stock Titan
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026 - ACCESS Newswire
eXoZymes Inc. (EXOZ) Climbs 3.92% to $5.3 as Biotech Stock Approaches Key ResistancePut Spread Alert - dars.gov.et
eXoZymes Inc. (EXOZ) Gains 3.82% as Shares Approach Key Resistance at $5.57Upthrust Pattern - dars.gov.et
eXoZymes Inc (EXOZ) Stock News Today - TradingKey
eXoZymes (EXOZ) Slides 5.15% to $4.6 as Biotech Selling Pressure IntensifiesPut Spread Alert - dars.gov.et
eXoZymes Inc. (EXOZ) Slips 1.1% as Shares Test Support Near $4.27Risk Reversal - vinanet.vn
eXoZymes Inc (EXOZ) Income Statement - TradingKey
eXoZymes Inc (EXOZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
eXoZymes Inc (EXOZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
eXoZymes Inc (EXOZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
eXoZymes Inc (EXOZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EXOZ|eXoZymes Inc|Price:4.550|Chg%:-0.050 - TradingKey
eXoZymes Inc. Revenue Breakdown – NASDAQ:EXOZ - TradingView
EXOZ|eXoZymes Inc|Price:4.500|Chg%:-0.210 - TradingKey
eXoZymes Inc (EXOZ) Cash Flow - TradingKey
eXoZymes Inc (EXOZ) Balance Sheet - TradingKey
eXoZymes Inc (EXOZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
eXoZymes Inc (EXOZ) Institutional Confidence - TradingKey
eXoZymes Inc. (EXOZ) Slides Amid Biotech Volatility: Key Levels to WatchDay Trade Opportunities - dars.gov.et
eXoZymes, Inc. (EXOZ) Stock Price, News, Quote & History - Yahoo! Finance Canada
Finanzdaten der Exozymes Inc-Aktie (EXOZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Exozymes Inc-Aktie (EXOZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Heltzen Michael | Chief Executive Officer |
Aug 25 '26 |
Buy |
7.51 |
350 |
2,630 |
14,203 |
| Korman Tyler Paz | Chief Scientific Officer |
Apr 09 '26 |
Sale |
10.53 |
750 |
7,894 |
729,123 |
| Korman Tyler Paz | Chief Scientific Officer |
Apr 08 '26 |
Sale |
10.04 |
750 |
7,530 |
729,873 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):